# A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

> **NCT07544056** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **BeBetter Med Inc** · enrollment: 446 (estimated)

## Conditions studied

- Locally Advanced Triple-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer

## Interventions

- **DRUG:** BEBT-209 capsules
- **DRUG:** Carboplatin Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection

## Key facts

- **NCT ID:** NCT07544056
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-06
- **Final completion:** 2030-12
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07544056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07544056, "A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07544056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*